The Fly | CING

Proprietary Drug Delivery Platform: Cingulate's core competitive advantage lies in its Precision Timed Release (PTR™) platform, which enables precise, multi-stage drug release profiles to optimize therapeutic effect and duration, differentiating it from conventional extended-release technologies.

Addressing Unmet Patient Needs: The PTR™ platform aims to overcome common limitations of existing ADHD treatments, such as delayed onset, inconsistent duration, and end-of-dose "crashes," by providing a rapid onset, smooth therapeutic profile, and consistent duration of action.

Advanced Clinical Pipeline: Cingulate boasts two lead candidates, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), both in late-stage clinical development for ADHD, demonstrating a robust pipeline targeting a significant market.

Clinical Trials May Fail: Their lead product candidates are in various stages of clinical trials, and there is no guarantee that these trials will be successful in demonstrating efficacy or safety, leading to potential delays or termination of development.

Regulatory Approval Uncertainty: Obtaining necessary regulatory approvals from agencies like the FDA is a lengthy, complex, and highly uncertain process. Delays or failure to secure approvals would prevent commercialization of their products.

Significant Capital Requirements: Cingulate is a clinical-stage company with no product revenue, requiring substantial additional financing to fund ongoing research, clinical development, and potential commercialization activities, which may not be available on favorable terms.